Avadel Pharmaceuticals Plc - Company Profile
Powered by 
All the sales intelligence you need on Avadel Pharmaceuticals Plc in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Avadel Pharmaceuticals Plc fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Avadel Pharmaceuticals Plc.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Avadel Pharmaceuticals Plc (Avadel) is a biopharmaceutical company that focuses on the development of products for the treatment of narcolepsy. Its marketed product Lumryz, is an FDA-approved, once-at-bedtime oxybate for the treatment of cataplexy or excessive daytime sleepiness (EDS) in adults with narcolepsy. The company's products are developed on its proprietary polymer-based technologies: Micropump, an oral sustained release microparticles platform, LiquiTime, a Micropump which is derived platform for liquid oral products, and Medusa that enables controlled release of injectables. It sells products in the US and Ireland. The company operates in St. Louis, Missouri in the US. Avadel is headquartered in Dublin, Ireland.
Headquarters
Ireland
Address
Ten Earlsfort Terrace, Dublin, 15
Website
www.avadel.com
Telephone
353 1 9015201
No of Employees
188
Industry
Pharmaceuticals and Healthcare
Revenue (2024)
$169.1M
Avadel Pharmaceuticals Plc premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Product: | Avadel |
| Lumryz (sodium oxybate) | Lumryz |
| Micropump | |
| XYZ | |
| XYZ | |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2026 | Ownership Changes | In February, the company was acquired by Alkermes Plc, a biopharmaceutical company. |
| 2025 | Regulatory Approval | In June, the company received Orphan Drug Designation from the US FDA for LUMRYZ (sodium oxybate) for extended-release oral suspension for the treatment of idiopathic hypersomnia. |
| 2024 | New Products/Services | In May, the company launched LUMRYZ (sodium oxybate) for extended-release oral suspension (CIII). |
Competitor Comparison
| Key Parameters | Avadel Pharmaceuticals Plc | Jazz Pharmaceuticals Plc | Hikma Pharmaceuticals Plc | Amneal Pharmaceuticals Inc | Elite Pharmaceuticals Inc |
|---|---|---|---|---|---|
| Headquarters | Ireland | Ireland | United Kingdom | United States of America | United States of America |
| City | Dublin | Dublin | London | Bridgewater | Northvale |
| State/Province | - | Dublin | England | New Jersey | New Jersey |
| No. of Employees | 188 | 2,890 | 9,603 | 8,500 | 68 |
| Entity Type | Private | Public | Public | Public | Public |
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Geoffrey M. Glass | Chairman | Executive Board | 2018 | 51 |
| Gregory J. Divis | Director; Chief Executive Officer | Executive Board | 2019 | 58 |
| Thomas S. McHugh | Chief Financial Officer | Senior Management | 2019 | 60 |
| Susan Rodriguez | Chief Operating Officer | Senior Management | 2025 | - |
| Polly Murphy | Chief Business Officer | Senior Management | 2024 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer